ExpertiseUpdated on 25 February 2026
Oxeltis _ Bridge the gap between biology and chemical matter...
About
We address this by:
Seamless integration of in silico design (CADD, SBDD, LBDD, AI/ML) in partnership with Molecular Forecaster (Montreal) and Assay development/in vitro biological screening in partnership with Partex.AI Labs
Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)
Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.
Oxeltis, France-based CRO specialized in medicinal and fine organic chemistry can support early small molecule drug disocvery programs to mature at Hit to Lead and Lead optimization stage.
Field
- Biotech, Pharma and Cosmetics
Organisation
Similar opportunities
Expertise
- Biotech, Pharma and Cosmetics
Elmeri Jokinen
CEO at Aurlide Oy
Turku, Finland
Expertise
- Healthcare
- Biotech, Pharma and Cosmetics
Sanjee Tawde
VP - Business Development & Sales at Partex.AI
Frankfurt, Germany
Partnership
Sandra von Meier
Head of Business Development Life Science at Terra Quantum AG
Munich, Germany